摘要
Background and question: Malignant cells characteristically possess high levels of proteases (e.g. plasminogen activator, cathepsin etc.), which should induce fibrinolysis. The DR- 70(tm) immunoassay quantifies the amount of fibrin degradation products (FDP) in the body. This test system has successfully been used for the detection of a number of cancers including lung, stomach, breast, rectum, liver, colon and uterus cancer. In this paper we tested the diagnostic validity of DR- 70(tm) relative to CA- 125 as a tumor marker for the detection of ovarian carcinoma. Methods: We have simultaneously investigated the serum activities of DR- 70(tm)and CA- 125 from 61 preoperative patients with histologically confirmed ovarian carcinoma. One hundred healthy blood donors served as control group. We measured the FDP utilizing the DR- 70(tm) ELISA as per test instructions of its manufacturer AMDL (Tustin, CA, USA). Results: Low levels of FDP measured by DR- 70(tm) have been detected in the serum of 100 apparently healthy persons (mean ± S.D., 0.41 ± 0.19 μ g/ml). Among the 61 ovarian carcinoma patients, DR- 70(tm) mean value (± S.D.) was 7.0 ± 10.5 μ g/ml in a range of 0.6 to 58.5 μ g/ml. The cut- off level for DR- 70(tm) was set at > 1.2 μ g/ml. The specificity was 100% , whereas the sensitivity was at 83.6% . Relative to CA- 125 a cut- off level of > 65 U/ml was applied. The comparable sensitivity of DR- 70(tm) was higher by 13.1 % . Conclusions: Malignant cells with high levels of proteases are significant contributors to fibrinolysis. The DR- 70(tm) immunoassay has been designed to measure the level of FDP in the serum. DR- 70(tm) represents a tumor marker with which ovarian carcinoma can be diagnosed at levels of sensitivity and specificity which compare favorably to those measured with CA- 125.
Background and question： Malignant cells characteristically possess high levels of proteases （e. g. plasminogen activator, cathepsin etc. ）, which should induce fibrinolysis. The DR-70（tm） immunoassay quantifies the amount of fibrin degradation products （FDP） in the body. This test system has successfully been used for the detection of a number of cancers including lung, stomach, breast, rectum, liver, colon and uterus cancer. In this paper we tested the diagnostic validity of DR-70（tm） relative to CA-125 as a tumor marker for the detection of ovarian carcinoma. Methods： We have simultaneously investigated the serum activities of DR-70（tm） and CA-125 from 61 preoperative patients with histologically confirmed ovarian carcinoma. One hundred healthy blood donors served as control group. We measured the FDP utilizing the DR-70 （tm） ELISA as per test instructions of its manufacturer AMDL （Tustin, CA, USA）. Results： Low levels of FDP measured by DR-70（tm） have been detected in the serum of 100 apparently healthy persons （mean ± S.D., 0. gl ±0. 19 μg/ml）. Among the 61 ovarian carcinoma patients, DR-70（tm） mean value （ ± S.D. ） was 7.0 ±10. 5 μg/ml in a range of 0. 6 to 58.5μg/ml. The cut - off level for DR-70（tm） was set at 〉 1.2 μg/ml. The specificity was 100%, whereas the sensitivity was at 83.6%. Relative to CA - 125 a cut - off level of 〉 65 U/ml was applied. The comparable sensitivity of DR-70（tm） was higher by 13. 1%.
